I received a telephone call recently from a man who was angry and upset. All he could say was, but I’m not dying, I’m not dying! I was finally able to calm him down enough to be able to get him to tell me his story. It seems that his doctor told him that it [...]
As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]
A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]
We have talked about it many times in past posts, the potential that many believe combination therapy can hold for better treatments for all cancers, including advanced prostate cancer. Combination therapy has made AIDS treatment as successful as it has become and it holds a similar promise for cancer treatment. An example of this potential [...]
In 2007 a Norwegian cancer therapeutics company, Algeta, presented data from a phase II study that showed a remarkable two-year survival advantage with its investigational drug, Alpharadin (radium-223), when used as a as a treatment for castrate resistant prostate cancer (CRPC). […]